There are currently no standard treatments that slow or stop Parkinson’s disease — available therapies address each patient’s individual symptoms. Now, a breakthrough study successfully identifies two existing antimalaria drugs that show promise in targeting disease progress.

The international team behind the study — including members from Nanyang Technological University (NTU) in Singapore and McLean Hospital and Harvard Medical School in Belmont, MA — reports the findings in the Proceedings of the National Academy of Sciences.

An estimated 10 million people worldwide are living with Parkinson’s disease — a progressive, neurological disorder that mostly strikes after middle age. As the disease unfolds, people gradually lose their ability to control their movements and find it increasingly difficult to walk, talk and look after themselves.


Continue Reading

READ FULL ARTICLE Curated publisher From Medical News Today